medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2012, Number 1

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2012; 28 (1)

Hemophilia: historical and genetic aspects

Castillo-González D

Language: Spanish
References: 34
Page:
PDF size: 153.88 Kb.


ABSTRACT

Hemophilia is a hemorrhagic disorder characterized by decreasing or absence of the procoagulant activity in factor VIII or IX. First descriptions of this disease are as old as mankind itself. During time, hemophilia has been called "royal disease" since different members of European royal families suffered from it. Currently, by molecular studies, it was found the causing genetic defect of this disease in hemophilic male members of Queen Victoria´s family; and it was found that her descendants suffered a severe hemophilia B. This disease phenotype is hemorrhagic; bleeding in different sites is observed which are mainly conditioned by the levels of the deficient factor. There are other factors participating in the variable phenotype characteristic of these patients, such as: intrinsic characteristics of factors VIII/IX, the presence of modifying genes and environment factors which influence on this disease severity. It is revised here the correlation genotype-phenotype in this disease through the most frequent mutations in each type of hemophilia. Concerning the presence of inhibitors, it is highlighted the current evidences in relation with risk factors related to its emergence and molecular aspects present in hemophilia variant B Leyden.


REFERENCES

  1. Mannucci PM. Ham-Wasserman Lecture: hemophilia and related bleeding disorders: a story of dismay and success. Hematology Am Soc Hematol Educ Program. 2002:1-9. PMID: 12446416.

  2. Bolton-Maggs P, Pasi JK. Haemophilias A and B. Lancet. 2003 May 24;361(9371):1801-9.

  3. Ingram GI. The history of haemophilia. J Clin Pathol. 1976 Jun;29(6):469-79.

  4. Giangrande P. Cronología de la hemofilia [internet]. Montréal, Québec: World Federation of Hemophilia, 2007 [citado 15 sept 2010]. Disponible en: http://www.wfh.org/index.asp?lang=EN

  5. Lannoy N, Hermans C. The royal disease-haemophilia A or B? A haematological mystery is finally solved. Haemophilia. 2010 Nov;16(6):843-7. doi: 10.1111/j.1365-2516.2010.02327.

  6. Pavlovsky A. Contribution to the pathogenesis of hemophilia. Blood. 1947 Mar;2(2):185-91.

  7. Biggs R, Douglas AS, Mac Farlane RG, Dacie JV, Pitney WR, Merskey. Christmas disease: a condition previously mistaken for haemophilia. Br Med J. 1952 Dec 27;2(4799):1378-82.

  8. Balkan C, Kavakli K, Karapinar D. Spinal epidural haematoma in a patient with haemophilia B. Haemophilia. 2006 Jul;12(4):437-40.

  9. Girolami A, Vettore S, Scandellari R, Allemand E, Girolami B. About the rarity of haemoptysis in congenital bleeding disorders. A report of five cases. Haemophilia. 2009 May;15(3):825-7.

  10. Castillo D, Almagro D, Machín S, Nuñez A, Macías I, Nordet I, et al. Hemorragias en sitios poco usuales en pacientes con hemofilia. XXI Congreso del grupo CLAHT y XX Congreso de la Sociedad Venezolana de Hematología. Isla de Margarita, Venezuela 2-5 Octubre 2009. (P055)

  11. Giannelli F, Green PM, Sommer SS, Poon M, Ludwig M, Schwaab R, et al. Haemophilia B: database of point mutations and short additions and deletions—eighth edition. Nucleic Acids Res. 1998 Jan 1;26(1):265-8.

  12. Kemball-Cook G, Tuddenham EG, Wacey AI. The factor VIII structure and mutation resource site: HAMSTeRS version 4. Nucleic Acids Res. 1998 Jan 1;26(1):216-9.

  13. White GC II, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. On behalf of the Factor VIII and Factor IX Subcommittee. Definitions in hemophilia recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001 Mar;85(3):560.

  14. Van den Berg HM, De Groot PHG, Fischer K. Phenotypic heterogeneity in severe hemophilia. J Thromb Haemost. 2007 Jul;5 (Suppl 1):151-6.

  15. Jayandharan GR, Srivastava A. The phenotypic heterogeneity of severe hemophilia. Semin Thromb Hemost. 2008 Feb;34(1):128-41.

  16. Goudemand J. Inhibitor developments in haemophilia A: the role of von Willebrand factor/factor VIII concentrates. Haemophilia. 2007 Dec;13 (Suppl 5):47-51.

  17. Dimichele D. Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia. 2002 May;8(3):280-7.

  18. Almagro D, Rubio R, González I, Díaz A, González A. Vida natural de los inhibidores del Factor VIII en pacientes hemofílicos. Rev Cubana Hematol Inmunol Hemoter. 1990;6:343-55.

  19. Rodríguez-Merchan EC, Lee CA. Inhibitors in patients with Haemophilia. Oxford: Blackwell Science; 2002.

  20. White GC. Prediction of inhibitors in hemophilia. J Thromb Haemost. 2008 Dec;6(12):2045-7.

  21. Viel KR, Ameri A, Abshire TC, Iyer RV, Watts RG, Lutcher C, et al. Inhibitors of Factor VIII in black patients with hemophilia. N Engl J Med. 2009 Apr 16;360(16):1618-27.

  22. Salvagno GL, Astermark J, Ekman M, Franchini M, Guidi GC, Lippi G, et al. Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation. Haemophilia. 2007 Jan;13(1):51-6.

  23. Kaveri SV, Dasgupta S, Andre S, Navarrete AM, Repesse´ Y, Wootla B, et al. Factor VIII inhibitors: role of von willebrand factor on the uptake of factor VIII by dendritic cells. Haemophilia. 2007 Dec;13 Suppl 5:61-4.

  24. Chitlur M, Warrier I, Rajpurkar M, Lusher JM. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006). Haemophilia. 2009 Sep;15(5):1027-31.

  25. Ter Avest PC, Fischer K, Mancuso ME, Santagostino E, Yuste VJ, Van Den Berg HM, et al. On behalf of the CANAL Study Group. Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice. J Thromb Haemost. 2008 Dec;6(12):2048-54.

  26. Gouw SC, Ter Avest PC, Van Helden PM, Voorberg J, Van Den Berg HM. Discordant antibody response in monozygotic twins with severe haemophilia A caused by intensive treatment. Haemophilia. 2009 May;15(3):712-17.

  27. Fakharzadeh SS, Kazazian HH Jr. Correlation between Factor VIII genotype and inhibitor development in hemophilia A. Semin Thromb Hemost. 2000;26(2):167-71.

  28. Veltkamp JJ, Meilof J, Remmelts HG, Van der Vlerk D, Loeliger EA. Another genetic variant of haemophilia B: haemophilia B Leyden. Scand J Haemat. 1970;7(2):82-90.

  29. Coyle TE, Spicer T, Michalovic D, Poiesz BJ. Moderate hemophilia B Leyden: identification by polymerase chain reaction, sequencing, and oligomer restriction. Am J Hemat. 1994 Jul;46(3):234-40.

  30. Crossley M, Ludwig M, Stowell KM, De Vos P, Olek K, Brownleet G. Recovery from hemophilia B Leyden: an androgen-responsive element in the Factor IX promoter. Science. 1992 Jul 17;257(5068):377-9.

  31. Picketts DJ, Mueller CR, Lillicrap D. Transcriptional control of the Factor IX gene: analysis of five Cis-acting elements and the deleterious effects of naturally occurring hemophilia B Leyden mutations. Blood. 1994 Nov 1;84(9):2992-3000.

  32. Brady JN, Notley C, Cameron C, Lillicrap D. Androgen effects on factor IX expression: in-vitro and in-vivo studies in mice. Br J Haematol. 1998 May;101(2):273-9.

  33. Kurachi S, Huo JS, Ameri A, Zhang K, Yoshizawa AC, Kurachi K. An age-related homeostasis mechanism is essential for spontaneous amelioration of hemophilia B Leyden. Proc Natl Acad Sci USA. 2009 May 12;106(19):7921-6.

  34. De Steenwinkel F, Wesseling J, Peters M, Van Ommen Ch. Symptomatic carrier of haemophilia B Leyden: a case report. Haemophilia. 2010 Nov;16(6):965-6. doi: 10.1111/j.1365-2516.2010.02281.x.




2020     |     www.medigraphic.com